$CELG News Be ready to play another market surge 12:25

New Post Public Reply Private Reply Replies (0) Message Board

Sep 30, 2014 at 11:34 AM

$CELG News

Be ready to play another market surge 12:25 p.m. Sept. 19, 2014 - The Trading Deck
14 stocks loved by top-performing fund managers 6:49 a.m. Sept. 18, 2014 - Philip van Doorn
Lululemon surges; RadioShack rebounds 3:24 p.m. Sept. 11, 2014 - Sue Chang
Major U.S. benchmarks rattle cage on first support 11:06 a.m. Sept. 10, 2014 - Michael Ashbaugh
Celgene shares up on news of positive late-stage drug trial 7:42 a.m. Sept. 4, 2014 - Ciara Linnane
How retail sector sets up stocks at the end of summer 3:32 p.m. Aug. 14, 2014 - The Trading Deck
S&P 500 retests the breakdown point 11:17 a.m. Aug. 14, 2014 - Michael Ashbaugh
S&P 500 ekes out another record close: stock market live blog recap 4:03 p.m. July 24, 2014 - blogs.marketwatch.com
Biotechs beat estimates, but the Street wants more 11:44 a.m. July 24, 2014 - Russ Britt
Biogen results crush consensus 4:55 p.m. July 23, 2014 - The Trading Deck
Nasdaq needs to turn up the volume 11:59 a.m. July 17, 2014 - The Trading Deck
Bull rolls on, but opportunities start to dwindle 1:52 p.m. July 10, 2014 - The Trading Deck
Reynolds rises on buyout report; Delta gains altitude 2:25 p.m. July 9, 2014 - Sue Chang
Celgene's arthritis drug fails a test, but company's stock rises anyway 1:23 p.m. July 9, 2014 - Russ Britt
Celgene shares slump as late-stage trial misses goal 7:27 a.m. July 9, 2014 - Ciara Linnane
S&P, Dow rattle cage on uncharted territory 11:20 a.m. July 1, 2014 - Michael Ashbaugh
S&P, Dow rattle cage on uncharted territory 10:54 a.m. July 1, 2014 - Michael Ashbaugh
Celgene's fourth stock split is a hit with investors as shares climb 1:02 p.m. June 19, 2014 - Russ Britt
Celgene shareholders approve 2-for-1 stock split 8:57 a.m. June 19, 2014 - Ciara Linnane
Celgene to increase buyback program to 1.15 bln shares from 575 mln 8:52 a.m. June 19, 2014 - Ciara Linnane

Biotech Stocks Rebound On Strong Earnings, New Drugs 5:32 p.m. Sept. 29, 2014 - Investors Business Daily
Agios to Present Data on AG-120 in November, Shares Rises - Analyst Blog 5:30 p.m. Sept. 29, 2014 - Zacks.com
3 Stocks Reiterated As A Buy: PFE, CELG, BIIB 4:44 p.m. Sept. 29, 2014 - TheStreet.com
Celgene Has A Very Bright Future Ahead 4:26 p.m. Sept. 29, 2014 - Seeking Alpha
Bullish on Tech, Drug, Online Ed, and Solar 11:44 a.m. Sept. 29, 2014 - Barrons.com
3 Likely Biotech Buyout Candidates 7:48 a.m. Sept. 29, 2014 - 247WallSt.com
Agios Pharmaceuticals Inc, Altria Group Inc Highlight CNBC's Stock Pops & Drops From September 26 9:33 a.m. Sept. 27, 2014 - benzinga.com
'Fast Money' Recap: Why Volatility Might Be a Good Thing 5:00 a.m. Sept. 27, 2014 - TheStreet.com
Agios hits new high 1:12 p.m. Sept. 26, 2014 - Seeking Alpha
Celgene: Jim Cramer's Favorite Biotech Juggernaut 12:22 p.m. Sept. 26, 2014 - Seeking Alpha
Agios' Early Drug-Trial Report Cheers Wall Street 12:21 p.m. Sept. 26, 2014 - Investors Business Daily
Jim Cramer's Stop Trading: Does Agios Pharmaceuticals Have a Monumental Cancer Treatment? 11:58 a.m. Sept. 26, 2014 - TheStreet.com
Technology Stocks Slide But Other Sectors Hold Up Better 5:55 p.m. Sept. 25, 2014 - Investors Business Daily
Short Sellers Make Moves in Key Biotech Stocks 9:54 a.m. Sept. 25, 2014 - 247WallSt.com
Celgene (CELG) Hits New Lifetime High Today 9:47 a.m. Sept. 25, 2014 - TheStreet.com
'Fast Money' Recap: What Market? The Focus Remains on Apple 5:00 a.m. Sept. 25, 2014 - TheStreet.com
Jim Cramer's 'Mad Money' Recap: Why You Can't Get Too Negative in This Market 8:24 p.m. Sept. 24, 2014 - TheStreet.com
Celgene's Otezla Label Expanded to Include Plaque Psoriasis - Analyst Blog 5:30 p.m. Sept. 24, 2014 - Zacks.com
Jim Cramer's Mad Dash: Celgene and Morgan Stanley Still Have Upside 10:58 a.m. Sept. 24, 2014 - TheStreet.com
Celgene (CELG) Rising Before The Market Opens 9:40 a.m. Sept. 24, 2014 - TheStreet.com

Oral OTEZLA® (apremilast) Approved by the U.S. Food and Drug Administration for the Treatment of Patients with Moderate to Severe Plaque Psoriasis 3:18 p.m. Sept. 23, 2014 - BusinessWire - BZX
Zeldes Haeggquist & Eck, LLP Announces Investigation of Celgene, Inc. 9:01 a.m. Sept. 22, 2014 - BusinessWire - BZX
Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 8:15 a.m. Sept. 19, 2014 - PR Newswire - PRF
Celgene Appoints Tuomo Pätsi as President of EMEAand Commits to Continue Delivering Innovative Solutionsto Meet Patient Needs Across the Region 8:02 a.m. Sept. 19, 2014 - BusinessWire - BZX
Study Data Release, Dividends and Shares Repurchases, Committee Recommendations, New Partners, and Upcoming Conferences - Research Reports on Celgene, Abbott, Actavis, UnitedHealth and Bristol-Myers 9:00 a.m. Sept. 16, 2014 - PR Newswire - PRF
Critical Alerts For CBS, Imperva Inc, Toyota Motor, Celgene and News Corp Released By InvestorsObserver 9:31 a.m. Sept. 11, 2014 - PR Newswire - PRF
New Center, Clinical Study Results, Collaborations, and Upcoming Event - Research Reports on Centene, Mallinckrodt, Infinity, Celgene and UnitedHealth 8:55 a.m. Sept. 8, 2014 - PR Newswire - PRF
Nuvilex Aims for Market Exclusivity with Orphan Drug Status While Eyeing Larger Cancer Market for Cell-in-a-Box Technology 9:06 a.m. Sept. 5, 2014 - ACCESSWIRE
Technical Data on Biotech Stocks - ARIAD Pharma, Tekmira Pharma, Arrowhead Research, Celgene, and Amgen 8:55 a.m. Sept. 4, 2014 - PR Newswire - PRF
Phase III FIRST™ (MM-020/IFM 07-01) Trial of REVLIMID® (lenalidomide) Plus Dexamethasone in Newly Diagnosed Multiple Myeloma Patients Who Are Not Candidates for Stem Cell Transplant Published in New England Journal of Medicine 7:31 a.m. Sept. 4, 2014 - BusinessWire - BZX
VentiRx Pharmaceuticals Provides Corporate and Clinical Update 8:00 a.m. Sept. 2, 2014 - PR Newswire - PRF
Upcoming Conferences Schedule, Clinical Trial Data Release Schedule, Milestone Payment, and Expansion of Partnership - Research Reports on Celgene, Actavis, Regeneron, ISIS and UnitedHealth 9:10 a.m. Aug. 29, 2014 - PR Newswire - PRF
Acquisitions, Clinical Study Results, Dividends, and Technical Updates - Research Reports on Mallinckrodt, Celgene, Actavis, UnitedHealth and Bristol-Myers 8:50 a.m. Aug. 21, 2014 - PR Newswire - PRF
Celgene Corporation to Present at Investor Conferences in September 8:30 a.m. Aug. 21, 2014 - BusinessWire - BZX
Bristol-Myers Squibb and Celgene Enter Clinical Collaboration Agreement to Evaluate Immunotherapy and Chemotherapy Combination Regimen 8:00 a.m. Aug. 20, 2014 - BusinessWire - BZX
Clinical Study in the Journal of Clinical Oncology Reports Patients with Diffuse Large B-Cell Lymphoma Receiving Oral REVLIMID with Standard R-CHOP Achieved 98% Overall Response Rate and 80% Complete Response Rate 7:30 a.m. Aug. 19, 2014 - BusinessWire - BZX
Collaborations, Financial Results, and Technical Updates - Research Reports on Actavis, UnitedHealth, Bristol-Myers Squibb, Celgene and Aetna 8:40 a.m. Aug. 12, 2014 - PR Newswire - PRF
Critical Alerts For Advanced Micro Devices, Celgene, Weibo, SunPower, and Time Warner Released By InvestorsObserver 9:31 a.m. Aug. 5, 2014 - PR Newswire - PRF
Celgene Reports Results from the Phase III POSTURE Study Evaluating Oral OTEZLA® in Ankylosing Spondylitis 7:00 a.m. July 9, 2014 - BusinessWire - BZX
Biotech Stocks Highlight -- Research on Celgene, Inovio Pharma, Amgen, and Array BioPharma 6:40 a.m. July 9, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AION UT Sets New Safety Standard in Euro NCAP 2026

The New Gold Standard in Safety for Small EVs Hop into your favorite auto forum and you'll hear more than a buzz—it's a full-blown ruckus. The reason? GAC’s AION UT just nabbed a 2026 Euro NCAP Five-Star Safety Rating. Now, this isn’t just another accolade in a crowded trophy room; it’s a statement, a seismic shift in how small electric vehicles stack up in terms...

BYD's Chip Mastery Amid China's Auto Supply Tensions

Chips, the New Battleground in Automotive Innovation Here we are, folks, knee-deep in a tech-driven car revolution where semiconductors aren't just the icing on the cake—they're the cake itself. As vehicles morph into veritable computers on wheels, reliance on chips is hitting a fever pitch. FYI, it's not just about making cars go; we're talking power management,...

MERACH Unveils W60 Plus: A Game Changer for Home Fitness

MERACH's Ambitious Leap into European Markets Walking is one of life's simple pleasures, but it's not always convenient in our work-from-home driven world. That's where MERACH's UltraWalk W60 Plus comes in, dropping anchor in Europe like a brand new ship with all the bells and whistles. What makes this walking pad different, you ask? It's designed to become a natural...

Nuix Leverages AI for Transformative Legal Review

Nuix Unveils AI Innovations in Legal Review Diving headfirst into the evolving world of legal technology, Nuix has just rolled out some serious upgrades to its eDiscovery toolkit. By plucking AI right out of the data science ethers, they're not just dabbling in futuristic tech—they're planting generative AI at the heart of legal review on their SaaS platform, Nuix...

Fosun Pharma Hits the Buyback Button: What's Next?

Fosun Pharma's Bold Move Well, if this isn't Fosun Pharma making some noise! Announcing an H-share repurchase plan worth up to HK$1 billion is like setting off fireworks amidst any investor's evening. They're hollering to the market, 'We see value, and we're doubling down on it.' Crunching the Numbers In the first half of 2026, Fosun Pharma's numbers weren't just a flash...

ACG Moves to Acquire Ke?kek for $7.85M Gold Venture

Here's the scoop: ACG Metals Limited is stepping up the game, attempting to snag the Ke?kek gold project in a deal worth up to $7.85 million. This move, they say, is all about bolstering the future of their gold production—and squeezing every ounce out of that Gediktepe facility in Türkiye. It's like squeezing juice from a lemon that's still got a bit of life left....

Hims & Hers Faces Class Action: Investors Beware

Allegations and Legal Pressure There's trouble brewing in the land of health and wellness apps, with Hims & Hers Health, Inc. (NYSE:HIMS) taking center stage. Slap on your glasses, folks, because this one's a doozy. A class-action lawsuit has exploded against the company and some of its officers—allegations flying as they focus on serious accusations of misleading...

53% of European Telecom Users Eye Provider Switch

Change Is Brewing in Europe's Telecom Markets Seems like Europe's telco scene is simmering. Over half of consumers in major European markets are giving their mobile providers the side-eye, ready to jump ship. That's putting the heat on operators who once banked on loyalty programs to keep their customer base intact. Diverse Loyalty Challenges Across Europe What's...

Multiconsult-Rejlers Merger Revs Up Nordic Market Power

A New Powerhouse in the Nordic Consultancy Space September 7, 2026, will likely be etched into the annals of stock market moves, marking the day two titans, Multiconsult and Rejlers, decided to tie the knot. This isn't your average merger. We're talking about a calculated Pan-Nordic push that's been building, and now, well, it's paying off with a potential powerhouse of...

Ping An Climbs Sustainability Ladder, Scores A+ Rating

Sustainability Triumph for Ping An: A+ Upgrade Ping An Insurance (Group) Company of China, Ltd. is having quite the moment, snagging an A+ in the latest 2026 Sustainability Rating from Hang Seng Indexes Company. This ain't just a one-time pat on the back—it's the third year of consecutive improvement. Looks like Ping An's focus on ESG efforts is finally getting the...